Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?

Hepatology

Volumn 31, Issue 1, 2000, Pages 211-218

  Poynard, Thierry ^a   Mchutchison, John ^b   Goodman, Zachary ^c   Ling, Mei Hsiu ^d   Albrecht, Janice ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MIXTURE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033965331     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510310131     Document Type: Article

References (16)

1. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. and the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
2. McHutchison J, Gordon S, Schiff E, Shiffman M, Lee W, Rustgi V, Goodman Z, et al. for the Hepatitis Interventional Therapy Group (HIT). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
3. Consensus Statement. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999;30:956-961.
4. Bedossa P. The French METAVIR cooperative group. Inter- and intraobserver variation in the assessment of liver biopsy of chronic hepatitis C. HEPATOLOGY 1994;20:15-20.
5. Bedossa P, Poynard T, for the French METAVIR group. An algorithm for the grading of activity in chronic hepatitis C. HEPATOLOGY 1996;24:289293.
6. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
7. Tong MJ, Hwang SJ, Lefkowitz, Lee SD, Co RL, Conrad A, Schmid P, et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994;9:587-591.
8. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterisation of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
9. Reichard O, Norkrans G, Fyden A, Braconier JH, Sōnnerborg A, Weiland O, for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.
10. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, et al. for the MULTIVIRC group. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999;116:378-386.
11. Manabe N, Chevalier M, Chossegros P, Causse X, Guerret S, Trepo C, Grimaud J-A. Interferon-α2b therapy reduces liver fibrosis in chronic non-A-nonB hepatitis: a quantitative histological evaluation. HEPATOLOGY 1993;18:1344-1349.
12. Castilla A, Prieto J, Fausto N. Transforming growth factor βI and α in chronic liver disease: effect of interferon alpha therapy. N Engl J Med 1991;324:933-940.
13. Shiffman M, Hoffman C, Thompson E, Feirreira-Gonzales A, Contos M, Koshy A, Luketic V, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. HEPATOLOGY 1997;26:780-785.
14. Poynard T, Bedossa P, Chevalier M, Mathurin P, Lemonier C, Trepo C, Couzigou P, et al. and the multicentre study group. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non A, non B hepatitis. N Engl J Med 1995;332:1457-1462.
15. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-3493.
16. Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. HEPATOLOGY 1998;27:1149-1156.